Content about Specialty Pharmacy

February 18, 2011

Technology is not only bringing more benefits to patients in the pharmacy, but it’s also offering them a host of products so they can be more involved in their health care. This was a theme at the National Council for Prescription Drug Programs’ educational summit, “Leveraging New Technologies: Impact on the Patient and the Healthcare Industry,” on Feb. 8 in Las Vegas.


February 17, 2011

The Obama administration’s proposed budget for 2012 contains an item that could change the game for biosimilars, according to published reports.

WASHINGTON — The Obama administration’s proposed budget for 2012 contains an item that could change the game for biosimilars, according to published reports.

According to the reports, the administration would lower the 12-year data exclusivity period for biotech drugs mandated in the healthcare-reform law to seven years.

February 17, 2011

Savient Pharmaceuticals announced changes to its management team as it gears up for the commercial launch of its chronic gout treatment.

EAST BRUNSWICK, N.J. — Savient Pharmaceuticals announced changes to its management team as it gears up for the commercial launch of its chronic gout treatment.

The drug maker appointed Louis Ferrari as its SVP corporate development, Christine Mikail as SVP and Stephen Davies as chief information officer and group VP.

February 17, 2011

Diplomat Specialty Pharmacy has hired a new CFO, the company said.

FLINT, Mich. — Diplomat Specialty Pharmacy has hired a new CFO, the company said.

Diplomat announced the appointment of Sean Whelan, citing his experience as a CFO in the healthcare industry. Whelan will report directly to president and CEO Phil Hagerman.

February 16, 2011

Amicus Therapeutics received good results from its mid-stage trial of a drug for a rare, genetic disorder, the drug maker said Wednesday.

CRANBURY, N.J. — Amicus Therapeutics received good results from its mid-stage trial of a drug for a rare, genetic disorder, the drug maker said Wednesday.

February 16, 2011

French drug maker Sanofi-Aventis will acquire U.S. biotech giant Genzyme for $20.1 billion, under an agreement the two companies announced Wednesday.

CAMBRIDGE, Mass. — French drug maker Sanofi-Aventis will acquire U.S. biotech giant Genzyme for $20.1 billion, under an agreement the two companies announced Wednesday.

February 14, 2011

The Food and Drug Administration has accepted for review an application for a pain medication designed to thwart drug abusers.

PALATINE, Ill. — The Food and Drug Administration has accepted for review an application for a pain medication designed to thwart drug abusers.

Acura Pharmaceuticals announced Monday the acceptance of King Pharmaceuticals’ application for Acurox (oxycodone hydrochloride). King developed the drug using Acura’s Aversion technology, which is designed to limit or impede the ability to abuse the drug by dissolving or crushing the pills and then injecting them.

February 14, 2011

Gilead Sciences has refiled an approval application with the Food and Drug Administration for an HIV drug, the drug maker said.

FOSTER CITY, Calif. — Gilead Sciences has refiled an approval application with the Food and Drug Administration for an HIV drug, the drug maker said.

Gilead said it had resubmitted its application for a single-tablet combination of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Johnson & Johnson subsidiary Tibotec Pharmaceuticals’ investigational drug TMC278 (rilpivirine hydrochloride) to treat HIV-1 infection in adults.

February 14, 2011

Following the exit of its oncology unit leader, drug maker Eli Lilly announced two executive changes.

INDIANAPOLIS — Following the exit of its oncology unit leader, drug maker Eli Lilly announced two executive changes.

Sue Mahony, currently SVP human resources and diversity, has been named SVP and president of Lilly Oncology, effective immediately. Mahony will remain a member of Lilly's executive committee. She succeeds John Johnson, who resigned from his post at Lilly last month to become CEO of Savient Pharmaceuticals.

February 11, 2011

Irish biotech company Elan and German drug maker Boehringer Ingelheim will collaborate to develop and manufacture antibody-based medicines.

DUBLIN — Irish biotech company Elan and German drug maker Boehringer Ingelheim will collaborate to develop and manufacture antibody-based medicines.

The two companies said BI would perform technical development, clinical manufacturing and regulatory filing support, while Elan would lead discovery, preclinical testing, clinical development and commercialization of the drugs. Financial terms of the deal were not disclosed.

February 11, 2011

The Food and Drug Administration announced Friday the approval of Waltham, Mass.-based Thermo Fisher’s QMS Everolimus Immunoassay, a test that monitors the blood for levels of Novartis’ drug Zortress (everolimus).

SILVER SPRING, Md. —The Food and Drug Administration announced Friday the approval of Waltham, Mass.-based Thermo Fisher’s QMS Everolimus Immunoassay, a test that monitors the blood for levels of Novartis’ drug Zortress (everolimus).

Zortress is a drug used to prevent rejection of transplanted kidneys.

“QMS Everolimus is the first FDA-cleared test physicians can use to maintain appropriate levels of the immunosuppressant everolimus,” FDA Center for Devices and Radiological Health director Jeffrey Shuren said.

February 11, 2011

The Food and Drug Administration has approved a drug for preventing preterm births.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug for preventing preterm births.

The agency announced Friday the approval of Baxter Pharmaceutical Solutions’ Makena (hydroxyprogesterone caproate) injection, for reducing the risk of preterm delivery before 37 weeks of pregnancy in pregnant women with a history of at least one spontaneous preterm birth.

February 11, 2011

The Food and Drug Administration has approved a painkiller delivered through a skin patch made by Mallinckrodt, the generic drug maker said Friday.

ST. LOUIS — The Food and Drug Administration has approved a painkiller delivered through a skin patch made by Mallinckrodt, the generic drug maker said Friday.

Mallinckrodt, part of Covidien, said the FDA approved its fentanyl transdermal system patch.

The patch is a generic version of Johnson & Johnson’s Duragesic. The drug, an opioid and Class II controlled substance, is used for managing persistent, moderate-to-severe pain that requires continuous opioid administration.

February 9, 2011

Women with ovarian cancer who received a drug made by Genentech lived longer without their disease becoming worse, according to a late-stage clinical trial.

SOUTH SAN FRANCISCO, Calif. — Women with ovarian cancer who received a drug made by Genentech lived longer without their disease becoming worse, according to a late-stage clinical trial.

Genentech, part of Swiss drug maker Roche, announced results from its phase-3 “OCEANS” study, in which women with recurring ovarian cancer received Avastin (bevacizumab) with gemcitabine and carboplatin, both chemotherapy drugs, followed by use of Avastin alone.

February 9, 2011

Sandoz is developing as many as 10 new follow-on biologics, according to published reports.

NEW YORK — Sandoz is developing as many as 10 new follow-on biologics, according to published reports.

Reuters, citing an interview with Sandoz head Jeff George in the German newspaper Handelsblatt, said the generics arm of Swiss drug maker Novartis had eight to 10 new biosimilar molecules in development.

February 8, 2011

The Food and Drug Administration has given expedited review to a drug for preventing hemodialysis failure in patients with end-stage kidney disease.

CAMBRIDGE, Mass. — The Food and Drug Administration has given expedited review to a drug for preventing hemodialysis failure in patients with end-stage kidney disease.

The FDA granted fast-track review status to the cell-based therapy Vascugel, made by Pervasis Therapeutics. The FDA grants the status to accelerate review of treatments for serious and life-threatening conditions, particularly those that address serious, unmet medical conditions.

February 7, 2011

The Food and Drug Administration has approved a generic cancer drug from Hospira.

LAKE FOREST, Ill. — The Food and Drug Administration has approved a generic cancer drug from Hospira.

The drug maker announced the approval of topotecan injection for treating small-cell lung cancer sensitive disease after first-line chemotherapy has failed.

The drug is a generic version of GlaxoSmithKline’s Hycamtin, which had sales of more than $140 million in 2010, according to Hospira.

February 4, 2011

AmerisourceBergen on Friday reported revenue of $19.9 billion, up 2.9%, for the first quarter ended Dec. 31.

VALLEY FORGE, Pa. — AmerisourceBergen on Friday reported revenue of $19.9 billion, up 2.9%, for the first quarter ended Dec. 31.

February 4, 2011

A specialty pharmacy focused on infertility is sponsoring a giveaway campaign to attract patients to its Web-based forum.

WALTHAM, Mass. — A specialty pharmacy focused on infertility is sponsoring a giveaway campaign to attract patients to its Web-based forum.

Village Fertility Pharmacy announced Thursday that users of its Village Voices site, an online forum and repository for infertility patients to post stories and share experiences launched in late 2010, will be eligible to win weekly giveaways through the month of February. Any user who submits a story or comments on a story will be entered to win a $30 gift card for use at the pharmacy.

February 3, 2011

A bill that would make the biggest changes to patent laws in more than half a century has drawn mixed responses from the drug industry.

WASHINGTON — A bill that would make the biggest changes to patent laws in more than half a century has drawn mixed responses from the drug industry.

The bill, S. 23, The Patent Reform Act of 2011, sponsored by Sen. Patrick Leahy, D-Vt., would make the first significant changes to patent laws in 60 years.

February 2, 2011

A coalition of companies, celebrities and health organizations has achieved its goal of screening 1 million Americans for risk of chronic obstructive pulmonary disease.

RIDGEFIELD, Conn. — A coalition of companies, celebrities and health organizations has achieved its goal of screening 1 million Americans for risk of chronic obstructive pulmonary disease.

Drive4COPD announced the milestone Wednesday, saying its aim was to change how COPD is addressed in the United States; Drive4COPD identified those at risk through its COPD Population Screener.

February 2, 2011

Nestlé Health Sciences completed its acquisition of a company that develops "medical foods" for such medical conditions as kidney disease, inflammatory bowel disease and colon cancer.

LUTRY, Switzerland — Nestlé Health Sciences completed its acquisition of a company that develops "medical foods" for such medical conditions as kidney disease, inflammatory bowel disease and colon cancer.

February 2, 2011

A new report developed by the Pharmaceutical Research and Manufacturers of America revealed that nearly 300 heart disease and stroke medicines are in development.

WASHINGTON — A new report developed by the Pharmaceutical Research and Manufacturers of America revealed that nearly 300 heart disease and stroke medicines are in development.

PhRMA said that while 299 medicines are in development by the nation's biopharmaceutical companies, there is a growing need for such drugs; African-Americans have a 1.5 times greater rate of heart disease death than other Americans and a 1.8 times greater rate of fatal stroke.

February 2, 2011

Pharmacy wholesaler H.D. Smith has promoted three of its executives.

SPRINGFIELD, Ill. — Pharmacy wholesaler H.D. Smith has promoted three of its executives.

The company announced Wednesday the promotion of Joseph Conda to SVP strategic planning and business development, Robert Appleby to corporate VP prescription products and Carolyn Webb to corporate VP marketing.

February 1, 2011

Specialty pharmacy provider BioScrip hopes to save $15 million through a cost-reduction and streamlining plan, the company said Monday.

ELMSFORD, N.Y. — Specialty pharmacy provider BioScrip hopes to save $15 million through a cost-reduction and streamlining plan, the company said Monday.

Much of the two-part initiative will be implemented this year and completed by next year. Savings will mostly come from overhead, reduction of spending and restructuring of employee-benefit programs.